Evidence map›Paper›PMID 31658181›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2019

Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral Suppression.

Nicholas Musinguzi, Jose Castillo-Mancilla, Mary Morrow, Helen Byakwaga, Samantha Mawhinney, Tricia H Burdo, Yap Boum, Conrad Muzoora, Bosco M Bwana, Mark J Siedner and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. Observational
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Nicholas MusinguziMbarara University of Science and Technology, Mbarara, Uganda.
Jose Castillo-MancillaUniversity of Colorado Anschutz Medical, Campus, Aurora, CO.
Mary MorrowUniversity of Colorado Anschutz Medical, Campus, Aurora, CO.
Helen ByakwagaMbarara University of Science and Technology, Mbarara, Uganda.
Samantha MawhinneyUniversity of Colorado Anschutz Medical, Campus, Aurora, CO.
Tricia H BurdoTemple University, Philadelphia, PA.
Yap BoumEpicentre, MSF, Mbarara, Uganda.
Conrad MuzooraMbarara University of Science and Technology, Mbarara, Uganda.
Bosco M BwanaMbarara University of Science and Technology, Mbarara, Uganda.
Mark J SiednerMassachusetts General Hospital and Harvard Medical School, Boston, MA.
Jeffrey N MartinUniversity of California San Francisco, San Francisco, CA.
Peter W HuntUniversity of California San Francisco, San Francisco, CA.
David R BangsbergOregon Health and Science, University-Portland State, University, Portland, OR.
Jessica E HabererMassachusetts General Hospital and Harvard Medical School, Boston, MA.
Mbarara University of Science and Technology · UGUniversity of California, San Francisco · USUniversity of Colorado Anschutz Medical Campus · USEpicentre Uganda · UGHarvard University · USMassachusetts General Hospital · USTemple University · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6M
AIDS and Cancer Specimen Resource (ACSR)UM1CA181255 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jeffrey Michael Bethony, Anna Coghill · 2013 to 2026
$56.7M
TB PREVENTION AND HIV IN THE HOMELESS--AN INTERVENTIONR01MH054907 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BANGSBERG, DAVID ROY · 1995 to 2014
$20.7M
Optimizing mHealth for adherence monitoring and interventionK24MH114732 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI HABERER, JESSICA ELIZABETH · 2017 to 2021
$800k
NCI NIH HHS UM1 CA181255NIAID NIH HHS P30 AI027763NIMH NIH HHS K24 MH114732NIMH NIH HHS R01 MH054907
6 · The paper itself

Abstract

backgroundResidual systemic inflammation, which is associated with non-AIDS clinical outcomes, may persist despite viral suppression. We assessed the effect of antiretroviral therapy (ART) adherence interruptions on systemic inflammation among Ugandans living with HIV who were virally suppressed.

settingWe evaluated adults initiating first-line ART at a regional referral hospital clinic in Mbarara, Uganda.

methodsPlasma concentrations of interleukin-6 (IL-6), D-dimer, soluble sCD14, sCD163, the kynurenine/tryptophan (K/T) ratio, and CD8 T-cell activation (HLA-DR/CD38 coexpression) were measured at baseline and 6 months after ART initiation among participants who achieved viral suppression (<400 copies/mL) at 6 months. ART adherence was monitored electronically. Time spent in an adherence interruption was computed as the percentage of days when the running average adherence was ≤10%. We fit adjusted linear regressions to evaluate the effect of time spent in an interruption on the log-transformed plasma concentrations of the inflammation biomarkers.

resultsOf 282 participants, 70% were women, and the median age was 34 years. At baseline, median CD4 and median log viral load were 135 cells per microliter and 5.1 copies per milliliter, respectively. In the adjusted analysis, a running average adherence of <10% was associated with higher sCD14 (+3%; P < 0.008), sCD163 (+5%; P = 0.002), D-dimer (+10%; P = 0.007), HLA-DR/CD8 (+3%; P < 0.025), IL-6 (+14%; P = 0.008), and K:T ratio (+5%; P = 0.002). These findings were largely robust to adjustment for average adherence, as well as higher thresholds of running average adherence, albeit with decreased statistical significance.

conclusionsIncreased time spent in adherence interruptions is associated with increased levels of inflammation, despite viral suppression above and beyond average adherence.

Indexed as

Medication AdherenceAdultAnti-HIV AgentsFemaleHIV InfectionsHumansInflammationMaleTime FactorsAnti-HIV Agents

Identifiers

PMID31658181
PMCPMC6820698
OpenAlexW2982692192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.